CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于增强嵌合抗原受体细胞的先进材料与递送系统
英文原题：Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells.
查看英文原题
Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）细胞疗法在免疫治疗中取得了重大成功和突破，但其临床广泛应用仍面临许多障碍，包括耗时较长、成本高和治疗实体瘤效果不佳。为应对这些挑战，研究者正探索如何将 CAR 细胞开发成更适用于临床的产品。本小型综述聚焦先进非病毒材料在离体 CAR-T 细胞转染中的应用，以获得更好的性能；还介绍与其他疗法联合、增强 CAR-T 治疗实体瘤效果的递送系统。此外，文章讨论了可在体内生成 CAR 细胞的靶向递送平台，将其视为一种具有低成本和便利性优势的突破性技术。最后，综述探讨 CAR 细胞疗法的发展方向和未来前景。
展开英文摘要原文
Chimeric antigen receptor (CAR) cell therapy is a great success and breakthrough in immunotherapy.
However, there are still lots of barriers to its wide use in clinical, including long time consumption, high cost, and failure against solid tumors. For these challenges, researches are deplored to explore CAR cells to more appliable products in clinical. This minireview focuses on the advanced non-viral materials for CAR-T transfection ex vivo with better performance, delivery systems combined with other therapy for enhancement of CAR-T therapy in solid tumors.
In addition, the targeted delivery platform for CAR cells in vivo generation as a breakthrough technology as its low cost and convenience. In the end, the prospective direction and future of CAR cell therapy are discussed.
论文信息
- 作者
- Li T、Luo R、Su L、Lv F、Mei L、Yu Y
- 单位
- Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, P. R. China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Small methods2023 Nov
- 原文标识
- PubMed 37653606 · DOI 10.1002/smtd.202300880